$9.09
0.11.11%
At close: -
$8.85
-0.24-2.62%
After Hours: 7:26 PM EDT
Comments
Loading...
Arcus Biosciences Insider Trading Activity | NYSE:RCUS | Benzinga
Track the latest Arcus Biosciences insider trading activity. Stay informed on recent buys, sells, and market impact for Arcus Biosciences stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Arcus Biosciences Inc Insiders Doing?
At Arcus Biosciences Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have report no sales in the last 30 days, meanwhile, insiders have reported buying a total of 1.40M shares for a total value of $15.40M.
Notable Recent Insider Buys and Sales
- On February 20, 2025, GILEAD SCIENCES INC, the company's 10% OWNER purchased 1.36M shares for $11 each.
- On February 27, 2025, TERRY ROSEN, the company's CHIEF EXECUTIVE OFFICER purchased 19.8K shares for $10.18 each.
- On February 27, 2025, YASUNORI KANEKO, the company's DIRECTOR purchased 20K shares for $10.06 each.
Ownership Statistics for Arcus Biosciences Inc
Shares Outstanding
105.841M
Insider Shares Owned
3.919M
Insider Percentage Owned
3.73%
Institutional Shares Held
33.215M
Institutional Percentage Held
31.4%
| Feb 27, 2025 | YASUNORI KANEKO | DIRECTOR | 20.00K | $10.06 | $201.20K | BUY | 3.90% | 533.45K | Feb 27 | View |
| Feb 27, 2025 | TERRY ROSEN | CHIEF EXECUTIVE OFFICER | 19.80K | $10.18 | $201.47K | BUY | 0.78% | 2.55M | Feb 27 | View |
| Feb 20, 2025 | GILEAD SCIENCES INC | 10% OWNER | 1.36M | $11.00 | $15.00M | BUY | 4.54% | 31.42M | Feb 18 | View |
| Jan 03, 2025 | Robert Goeltz II | CHIEF FINANCIAL OFFICER | -3.59K | $15.00 | -$53.91K | SELL | -5.64% | 60.14K | Dec 31 | View |
| Dec 04, 2024 | Alexander Azoy | CHIEF ACCOUNTING OFFICER | -201.00 | $15.32 | -$3.08K | SELL | -1.04% | 19.07K | Dec 02 | View |
| Aug 15, 2024 | Alexander Azoy | CHIEF ACCOUNTING OFFICER | -1.36K | $14.97 | -$20.31K | SELL | -6.64% | 19.07K | Aug 13 | View |
| Mar 29, 2024 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -11.55K | $17.55 | -$202.72K | SELL | -5.09% | 215.25K | Mar 27 | View |
| Mar 20, 2024 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -13.45K | $17.92 | -$240.94K | SELL | -5.60% | 226.80K | Mar 18 | View |
| Feb 28, 2024 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -58.63K | $20.09 | -$1.18M | SELL | -19.62% | 240.25K | Feb 26 - Feb 27 | View |
| Feb 28, 2024 | Juan Jaen | PRESIDENT | -27.03K | $20.09 | -$543.19K | SELL | -1.74% | 1.53M | Feb 26 - Feb 27 | View |
| Jan 31, 2024 | GILEAD SCIENCES INC | 10% OWNER | 15.24M | $21.00 | $320.00M | BUY | 102.80% | 30.06M | Jan 29 | View |
| Jan 04, 2024 | Robert Goeltz II | CHIEF FINANCIAL OFFICER | -2.00K | $20.00 | -$40.08K | SELL | -3.72% | 51.83K | Jan 02 | View |
| Jan 04, 2024 | Juan Jaen | PRESIDENT | -6.97K | $20.09 | -$140.13K | SELL | -0.46% | 1.52M | Jan 02 | View |
| Dec 26, 2023 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -21.52K | $17.76 | -$382.21K | SELL | -7.68% | 258.88K | Dec 22 | View |
| Dec 05, 2023 | Alexander Azoy | CHIEF ACCOUNTING OFFICER | -282.00 | $14.95 | -$4.22K | SELL | -2.37% | 11.60K | Dec 01 | View |
| Sep 26, 2023 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -21.37K | $19.99 | -$427.17K | SELL | -6.59% | 302.69K | Sep 22 | View |
| Jul 31, 2023 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -45.00K | $20.25 | -$911.25K | SELL | -11.79% | 336.57K | Jul 28 | View |
| Jul 05, 2023 | Alexander Azoy | CHIEF ACCOUNTING OFFICER | -1.02K | $20.41 | -$20.78K | SELL | -8.07% | 11.60K | Jul 03 | View |
| Jun 30, 2023 | GILEAD SCIENCES INC | 10% OWNER | 1.01M | $19.26 | $19.45M | BUY | 7.31% | 14.82M | Jun 28 | View |
| Jun 26, 2023 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -12.44K | $19.12 | -$237.80K | SELL | -3.16% | 381.57K | Jun 22 | View |
| Jun 16, 2023 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -12.56K | $19.35 | -$243.09K | SELL | -3.09% | 394.00K | Jun 16 | View |
| Jun 09, 2023 | Robert Goeltz II | CHIEF FINANCIAL OFFICER | -4.05K | $20.04 | -$81.14K | SELL | -6.38% | 59.39K | Jun 07 | View |
| Mar 20, 2023 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -8.73K | $16.81 | -$146.73K | SELL | -2.10% | 406.22K | Mar 16 | View |
| Jan 30, 2023 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -1.90K | $23.53 | -$44.70K | SELL | -0.46% | 414.95K | Jan 26 - Jan 27 | View |
| Dec 16, 2022 | Robert Goeltz II | CHIEF FINANCIAL OFFICER | -2.45K | $30.75 | -$75.43K | SELL | -17.50% | 11.57K | Dec 16 | View |
| Dec 16, 2022 | Carolyn Tang Attorney-in-Fact | GENERAL COUNSEL | -2.52K | $30.75 | -$77.58K | SELL | -8.11% | 28.58K | Dec 16 | View |
| Dec 16, 2022 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -16.48K | $30.75 | -$506.82K | SELL | -10.04% | 147.61K | Dec 16 | View |
| Dec 16, 2022 | Juan Jaen | PRESIDENT | -4.44K | $30.75 | -$136.41K | SELL | -0.31% | 1.44M | Dec 16 | View |
| Dec 16, 2022 | TERRY ROSEN | CHIEF EXECUTIVE OFFICER | -13.04K | $30.75 | -$401.07K | SELL | -0.35% | 3.68M | Dec 16 | View |
| Sep 20, 2022 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -12.68K | $26.28 | -$333.15K | SELL | -8.83% | 130.94K | Sep 16 | View |
| Jun 21, 2022 | Carolyn Tang Attorney-in-Fact | GENERAL COUNSEL | -2.92K | $21.45 | -$62.67K | SELL | -10.89% | 23.91K | Jun 16 - Jun 17 | View |
| Jun 21, 2022 | TERRY ROSEN | CHIEF EXECUTIVE OFFICER | -8.85K | $21.45 | -$189.91K | SELL | -0.24% | 3.66M | Jun 16 - Jun 17 | View |
| Jun 21, 2022 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -12.70K | $21.45 | -$272.29K | SELL | -9.67% | 118.62K | Jun 16 - Jun 17 | View |
| Jun 21, 2022 | Juan Jaen | PRESIDENT | -4.87K | $21.45 | -$104.46K | SELL | -0.34% | 1.43M | Jun 16 - Jun 17 | View |
| Mar 18, 2022 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -9.62K | $31.62 | -$304.09K | SELL | -8.32% | 105.98K | Mar 16 | View |
| Dec 22, 2021 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -34.82K | $41.48 | -$1.44M | SELL | -27.76% | 90.59K | Dec 20 | View |
| Dec 20, 2021 | Carolyn Tang Attorney-in-Fact | GENERAL COUNSEL | -1.11K | $40.12 | -$44.50K | SELL | -5.94% | 17.56K | Dec 16 - Dec 17 | View |
| Dec 20, 2021 | Robert Goeltz II | CHIEF FINANCIAL OFFICER | -1.11K | $40.12 | -$44.38K | SELL | -13.61% | 7.02K | Dec 16 - Dec 17 | View |
| Dec 20, 2021 | Juan Jaen | PRESIDENT | -1.97K | $40.12 | -$79.16K | SELL | -0.11% | 1.77M | Dec 16 - Dec 17 | View |
| Dec 20, 2021 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -12.68K | $40.12 | -$508.68K | SELL | -9.18% | 125.42K | Dec 16 - Dec 17 | View |
| Dec 20, 2021 | TERRY ROSEN | CHIEF EXECUTIVE OFFICER | -5.24K | $40.12 | -$210.33K | SELL | -0.87% | 595.57K | Dec 16 - Dec 17 | View |
| Sep 22, 2021 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -47.50K | $35.35 | -$1.68M | SELL | -29.62% | 112.84K | Sep 20 - Sep 21 | View |
| Jun 21, 2021 | Carolyn Tang Attorney-in-Fact | GENERAL COUNSEL | -2.92K | $23.89 | -$69.65K | SELL | -15.95% | 15.36K | Jun 16 - Jun 17 | View |
| Jun 21, 2021 | TERRY ROSEN | CHIEF EXECUTIVE OFFICER | -8.83K | $23.89 | -$211.01K | SELL | -1.48% | 589.57K | Jun 16 - Jun 17 | View |
| Jun 21, 2021 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -8.83K | $23.89 | -$211.01K | SELL | -6.13% | 135.34K | Jun 16 - Jun 17 | View |
| Jun 21, 2021 | Juan Jaen | PRESIDENT | -4.86K | $23.89 | -$116.05K | SELL | -0.27% | 1.77M | Jun 16 - Jun 17 | View |
| Jun 21, 2021 | William Grossman | CHIEF MEDICAL OFFICER | -7.07K | $23.89 | -$168.81K | SELL | -25.42% | 20.72K | Jun 16 - Jun 17 | View |
| Jun 07, 2021 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -1.04K | $24.91 | -$26.01K | SELL | -0.87% | 119.17K | Jun 04 | View |
| Apr 26, 2021 | YASUNORI KANEKO | DIRECTOR | 4.13K | $31.37 | $129.65K | BUY | 3.06% | 139.08K | Apr 23 | View |
| Apr 26, 2021 | William Grossman | CHIEF MEDICAL OFFICER | -4.13K | $31.37 | -$129.65K | SELL | -38.09% | 6.72K | Apr 23 | View |
| Apr 02, 2021 | KATHRYN FALBERG | DIRECTOR | 20.00K | $28.35 | $567.00K | BUY | 12.30% | 182.61K | Mar 31 | View |
| Mar 18, 2021 | William Grossman | CHIEF MEDICAL OFFICER | -2.13K | $35.03 | -$74.51K | SELL | -16.39% | 10.85K | Mar 16 | View |
| Mar 18, 2021 | Jennifer Jarrett | CHIEF OPERATING OFFICER | -8.66K | $35.03 | -$303.39K | SELL | -6.89% | 116.97K | Mar 16 | View |
| Feb 02, 2021 | GILEAD SCIENCES INC | 10% OWNER | 5.65M | $39.00 | $220.35M | BUY | 68.38% | 13.91M | Jan 31 | View |
| Dec 18, 2020 | William Grossman | — | -2.12K | $31.35 | -$66.37K | SELL | -23.94% | 6.73K | Dec 16 | View |
| Sep 09, 2020 | Robert Goeltz II | — | 5.00K | $21.57 | $107.85K | PURCHASE | ∞ | 5.00K | Sep 09 | View |
| Aug 11, 2020 | TERRY ROSEN | — | 43.70K | $22.86 | $999.31K | PURCHASE | 1.21% | 3.67M | Aug 07 - Aug 10 | View |
| Aug 04, 2020 | William Grossman | — | 200.00 | $19.72 | $3.94K | PURCHASE | 50.00% | 600.00 | Jul 31 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.